GenoME Diagnostics

Belfast, United Kingdom Founded: 2020 • Age: 6 yrs
An in-vitro diagnostic test for ovarian cancer is developed.
Annual revenue - Latest available
Total funding $2.1M 2 rounds
Employees 2 Tracked headcount
Investors 3 Known backers
Products 1 Services tracked
Competitors 10 Brand Intelligence

About GenoME Diagnostics

GenoME Diagnostics is a company based in Belfast (United Kingdom) founded in 2020. GenoME Diagnostics has raised $2.1 million across 2 funding rounds from investors including Qubis, Deepbridge Capital and Co-Fund NI. The company has 2 employees as of January 31, 2022. GenoME Diagnostics offers products and services including OvaME. GenoME Diagnostics operates in a competitive market with competitors including AOA, Aspira Women's Health, KOKO Medical, VOC Diagnostics and Avant Diagnostics, among others.

  • Headquarter Belfast, United Kingdom
  • Employees 2 as on 31 Jan, 2022
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Genome Diagnostics Ltd
  • Date of Incorporation 31 Jan, 2020
  • Jurisdiction BELFAST, NORTHERN IRELAND
Operational Areas
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Total Equity Funding
    $2.1 M (USD)

    in 2 rounds

  • Latest Funding Round
    $1.68 M (USD), Seed

    Mar 03, 2023

  • Investors
    Qubis

    & 2 more

  • Employee Count
    2

    as on Jan 31, 2022

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of GenoME Diagnostics

GenoME Diagnostics offers a comprehensive portfolio of products and services, including OvaME.

Product name locked
Category locked
Primary

Blood test for early and accurate ovarian cancer diagnosis.

Funding Insights of GenoME Diagnostics

GenoME Diagnostics has successfully raised a total of $2.1M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $1.68 million completed in March 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in GenoME Diagnostics

GenoME Diagnostics has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Qubis, Deepbridge Capital and Co-Fund NI.

All
Venture Fund
Investor Description Founded Year Domain Location
Qubis is engaged in commercializing academic research from Queen's University.
Locked Locked Locked
Deepbridge Capital is focused on tax-efficient investment opportunities.
Locked Locked Locked
-
Locked Locked Locked
Premium access

Investor details for GenoME Diagnostics

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by GenoME Diagnostics

Investments
Premium access

Investment portfolio details for GenoME Diagnostics

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - GenoME Diagnostics

Premium access

Detailed financials for GenoME Diagnostics

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Genome Diagnostics Comparisons

GenoME Diagnostics Primary company
Description
An in-vitro diagnostic test for ovarian cancer is developed.
Location
Belfast, United Kingdom
Founded Year
2020
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
2
As of 2022
Premium access

Peer comparison for GenoME Diagnostics

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of GenoME Diagnostics

GenoME Diagnostics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as AOA, Aspira Women's Health, KOKO Medical, VOC Diagnostics and Avant Diagnostics, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Business consultancy services are provided for the biopharma industry.
Locked Locked Locked
Diagnostic solutions for ovarian cancer risk in women are provided.
Locked Locked Locked
Postpartum hemorrhage addressed by catheter-based medical device for women.
Locked Locked Locked
Developer of diagnostic solutions to detect ovarian cancer
Locked Locked Locked
Microarray technology is utilized for early ovarian cancer detection.
Premium access

Detailed competitors of GenoME Diagnostics

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Genome Diagnostics

Premium access

Complete news archive for GenoME Diagnostics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about GenoME Diagnostics

GenoME Diagnostics was founded in 2020 and raised its 1st funding round 1 year after it was founded.

GenoME Diagnostics is headquartered in Belfast, United Kingdom. It is registered at Belfast, Northern Ireland, United Kingdom.

Shannon Beattie is the current CEO of GenoME Diagnostics.

GenoME Diagnostics is a funded company, having raised a total of $2.1M across 2 funding rounds to date.

As of Jan 31, 2022, the latest employee count at GenoME Diagnostics is 2.

GenoME Diagnostics was established in 2020 in Belfast, United Kingdom. Focus is placed on the biotechnology and diagnostics sector, where an in-vitro blood test known as OvaME is created. Levels of patented DNA methylation markers are measured in blood samples through droplet digital PCR to identify ovarian cancer. Operations center on test development and validation for clinical use.

GenoME Diagnostics's top competitors include Aspira Women's Health, AOA and KOKO Medical.

GenoME Diagnostics offers OvaME.

GenoME Diagnostics has 3 investors. Key investors include Qubis, Deepbridge Capital, and Co-Fund NI.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available